Founder & CEOFounder & CEO
Macro Supplies® · Full-timeMacro Supplies® · Full-timeJul 2022 - Mar 2024 · 1 yr 9 mosJul 2022 - Mar 2024 · 1 yr 9 mosManchester, England, United KingdomManchester, England, United Kingdom
WAKAME THIS WAY
Sea vegetables are another important component of the Okinawan diet.2588 Sea veggies have been associated with significantly lower all-cause mortality among those in Japan eating seaweed five or more times a week compared to fewer than three times.2589 In addition to being an excellent source of trace minerals, sea vegetables have multiple unique components, including the olive-brown carotenoid fucoxanthin2590 and a type of fiber called porphyran found to have lifespan-extending effects in model organisms.2591
One way seaweed could contribute to longevity is by lowering high blood pressure. With seaweed consumption associated with better blood pressure control in both children2592 and adults,2593 researchers decided to put it to the test and found significantly lower blood pressures from 6 (but not 4) g a day for a month of dried wakame (the sea vegetable in seaweed salad). A nice thing about whole food, plant-based interventions is that you sometimes get good side effects. In this study, one participant who had been suffering from gastritis saw their stomach inflammation resolved, and another’s chronic headaches disappeared.2594 Seaweed salad may also boost immune function, as I note in the Preserving Your Immune System chapter.
A Comprehensive Analysis into the Therapeutic Application of Natural Products as SIRT6 Modulators in Alzheimer’s Disease, Aging, Cancer, Inflammation, and Diabetes
Natural products such as isoquercetin, luteolin, and cyanidin act as SIRT6 activators, whereas vitexin, catechin, scutellarin, fucoidan, etc. work as SIRT6 inhibitors. It is noteworthy to mention that quercetin acts as both SIRT6 activator and inhibitor depending on its concentration used. Although none of them were found as highly selective and potent modulators of SIRT6, they could serve as the starting point for developing selective and highly potent scaffolds for SIRT6.
It says that fucoidan is un inhibitor of SIRT6
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164879/
Cyanidin, which is the most potent SIRT6 activator, has been shown to produce a 55-fold increase in SIRT6 activity compared to the 3–fold to 10-fold increase for the others
What about it?
Quoting from the first article:
“Fucoidan is a polysaccharide which is naturally found in seaweeds and brown algae [88]. It has been reported to possess antioxidant, anticancer, anti-inflammatory, antidiabetic, and immunomodulatory effects [88]. Fucoidans extracted from the Sargassum filipendula and Laminaria japonica has been shown to exhibit antioxidant activity greater than vitamin C [102,103,104]. A recent report mentioned that its antioxidant activity is attributed to higher scavenging of nitric oxide than the most widely used synthetic antioxidants, including butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT) [88]. It was identified and isolated from Fucus distichus fungus and was investigated to determine its SIRT6 modulation activity and the results depicted a considerable increase in deacetylation activity of SIRT6 [58]. Researchers have reported that fucoidan showed SIRT6 specific action since it strongly enhanced SIRT6 deacetylation activity as compared with its SIRT1-SIRT3 isoforms deacetaylation activity. Furthermore, fucoidan-riched five microalgal extracts obtained from Fucus distichus**, Fucus vesiculous, Cytoseira tamariscofolia, Cytoseira nodacaulis, and Alaria esculenta showed significant amplification of SIRT6 activity [58]. Most importantly, it exhibited dose-dependent SIRT6 stimulating activity [58]. Fucoidan induced apoptosis in HepG2 liver cancer cells through the upregulation of p53 and p14, as well as the stimulation of caspases activity. It is noteworthy to mention that overexpression of SIRT6 is associated with the induction of apoptosis in cancer cells. Furthermore, gluconeogenesis was inhibited by fucoidan through the stimulation of SIRT6 by p53, which in turn led to an enhanced level of FoxO1 [89]. It has also been reported that fucoidan provides antidiabetic action by inhibiting α-amylase and α-glucosidase. Moreover, the antidiabetic property of fucoidan is attributed to activate the PI3K/PKB pathway, which regulates insulin production and stimulates GLUT4 translocation [91]. Implications of fucoidan have also been identified in healing inflammation via inhibition of NO production, downregulation of iNOS, COX-2, IL-1 β, TNF-α, NF- κB expression, and regulation of ERK, JNK, MAPK, and Akt pathways [88,90].”
Footnote 58 goes to:
…which, in turn, shows this:
I take donotage’s sirt 6 product. Unfortunately some statins are said to down regulate sirt 6 (and I take a 40/10 simvastatin ezetimibe combo), so I take the product with my statins. Ive wanted to get my hands on fluvastatin but not available in India sellers so far or the countries ive been to abroad which is said to enhance sirt 6
This was a study where sirt 6 activator was taken with statins, interesting findings
I have Fucoidan in one of my sets of HDAC inhibitors, but I don’t have anything that I can say save that it is not that one that I take.
Are you still taking the brown algae? Any positive results to speak of?
Fluorotannins… Drapeau … for stem cell release… still I’m concerned about long term stem cell release
Best source species of brown algae for Fucoidan
Here is a preliminary table of ~10 brown-algae species with reported data (yield, composition) for their Fucoidan-type sulfated polysaccharides. Use this as a starting point for your sourcing/feasibility analysis. Many gaps remain (particularly supply-chain, consistent extraction yield, standardized bioactivity), so this is more of a “rolling dossier” than a finished sheet.
| # | Species (Brown Alga) | Approximate Yield / Dry Weight | Key Compositional / Structural Notes | Practical Sourcing Comment |
|---|---|---|---|---|
| 1 | Cystoseira barbata (Order Fucales, Turkey coast) | ~ 6.44 % ± 1.44 on dry weight basis. (Herald Open Access) | Yield highest in spring/fall. Extraction by acid. Contains fucose-rich polymer. (Herald Open Access) | Moderate yield; localised region; harvest season matters. |
| 2 | Sargassum vulgare (same study) | ~ 3.84 % ± 1.14 (dry weight) (Herald Open Access) | Lower yield compared to Cystoseira in same environment. Seasonal variation. | Sargassum genus large; many species—need species-level sourcing. |
| 3 | Cystoseira compressa | ~ 3.04 % ± 1.77 (dry weight) (Herald Open Access) | Similar environment, lower yield. | Less attractive from yield perspective. |
| 4 | Fucus vesiculosus (Order Fucales) | Broad reported range 9-11 % (older literature) (PubMed) | Very well studied species; many fractions; high fucose content (> 90% in some). (ResearchGate) | Good baseline “classic” source—well studied; supply may be seasonal. |
| 5 | Ascophyllum nodosum | Literature indicates variation; older data shows ~6-8 % in some studies. (Semantic Scholar PDFs) | Known for unique fucoidan (“ascophyllan”) containing uronic acids. (ScienceDirect) | Good supply chain in North Atlantic; unique composition may affect function. |
| 6 | Laminaria japonica (aka Saccharina japonica) | Reported: in one case ~22.67 % yield in Sargassum horneri and L. japonica using method I in one Turkish study. (Semantic Scholar PDFs) | High potential yield (subject to extraction method). One recent study: ~2.44 % yield for the species under enzyme-assisted extraction. (Nature) | Large biomass species; cultivated in Asia; extraction method matters drastically. |
| 7 | Undaria pinnatifida (wakame) | Included in reviews (exact yield data less uniform) (Wikipedia) | Generally “galactofucan” type (fucose + galactose) which may alter bioactivity. (Frontiers) | Attractive from supply standpoint (cultivated); structural variability needs control. |
| 8 | Macrocystis pyrifera (giant kelp) | Yields less clearly tabulated in the major reviews. (Mentioned in context) (Frontiers) | Large biomass; used in bio‐mass applications; fucoidan fractions vary. | Good scale potential; but need species/harvest/extraction controls. |
| 9 | Sargassum fusiforme | One recent study (2025) reported ~2.44% yield for S. japonica—not S. fusiforme—but S. fusiforme shown good bioactivity. (Nature) | Shows promising antioxidant/antitumour activity. | May be niche; supply chain may be limited; good for differentiated product. |
| 10 | Turbinaria ornata | In Gulf of Mannar study: ~5.83 % yield in September for T. ornata with water extraction. (ijpsonline) | Less widely studied; newer source. | Attractive for innovation; but may present supply/consistency risk. |
If you like, I can expand this to ~30 species (with advanced filtering: yield > 3 %, cultivated status, documented bioactivity) into a downloadable spreadsheet (CSV/Excel) for your product-development pipeline.
I asked CGPT to help identify sources for these, avoiding China (due to pollution, supply chain, and Quality Control / trust issues), and here are the results.
I think these are the original manufacturers, not retail brands - so you need to do some digging for the most cost-effective retail brands that use one of these suppliers. Please post any results you get and like. Perhaps a strategy is to contact these suppliers and ask what retail companies use their raw materials in a supplement product?
For oral nutraceuticals, once you filter by:
you end up with a surprisingly short list of suppliers that are actually worth talking to.
Below is a tight, practical shortlist I’d treat as primary candidates.
Why they’re top-tier
Species and origin
Scientific & clinical support
Use-case fit
Best if you want:
If you only talk to one true fucoidan manufacturer for an oral product, it should be Marinova.
Why they belong on the shortlist
Japanese company producing high-purity fucoidan from Okinawa mozuku (Cladosiphon okamuranus), a traditional edible brown seaweed. (kanehide-bio.co.jp)
Their English materials emphasise:
Process & QC
Evidence they’re supplement-grade, not just lab-scale
Use-case fit
Ideal if you want:
Between Marinova (Fucus/Undaria) and Kanehide (mozuku) you essentially cover the two most serious, non-Chinese, supplement-grade fucoidan platforms with human data and real food-safety systems.
These are appropriate if you:
What they offer
Relevance for you
What they offer
Relevance
What they offer
Relevance
If your goal is an evidence-driven oral nutraceutical rather than a generic kelp capsule:
First-line technical conversations
Secondary / whole-food partners
Everyone else we discussed earlier (Macrocystis/Sargassum/Turbinaria/Cystoseira) is, at present, either cosmetic-oriented, agri-focused, or not sufficiently mature as a standardised nutraceutical fucoidan supplier outside China and Japan.
If you want, I can next draft a supplier due-diligence checklist (QC, structural analytics, human data, pricing/tonnage) tailored specifically to fucoidan so you can send a standardised technical questionnaire to Marinova and Kanehide first, and then to your chosen whole-seaweed partners.
